Track BioNTech SE — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

BioNTech SE BNTX · Stock Open BioNTech SE in new tab

85.60 USD
EPS
-6.83
P/B
1.07
ROE
-8.14
Beta
1.33
Target Price
112.40 USD
BioNTech SE logo

BioNTech SE

🧾 Earnings Recap – Q3 2026

BioNTech shares rose 3.6% after earnings, with investors responding to encouraging lung-cancer data and progress toward pivotal trials. The pipeline remains the main catalyst; the transcript provides no new financial outlook or near-term commercial catalyst.

  • Updated data for gotistobart showed median overall survival nearly doubled versus standard-of-care chemotherapy in a non-pivotal stage of its global phase III trial; the pivotal stage is ongoing.
  • Pumitamig plus LSD showed encouraging early efficacy and manageable safety in small cell lung cancer, including first-line patients, but the data are early.
  • BioNTech and Gilead agreed to evaluate pumitamig with a TROP2-directed ADC in a planned phase III trial for first-line metastatic PD-L1-low or -negative triple-negative breast cancer, subject to regulatory approval.
  • BioNTech is running four registrational programs for pumitamig in non-small cell lung cancer and is using combination data to inform potential chemotherapy-free trials.
  • CEO Uğur Şahin said this was his final earnings call; Guido Oelkers is expected to take office as CEO by February 1 at the latest.
📅
Loading chart...
Key Metrics
Earnings dateMarch 9, 2027
EPS-6.83
Book Value80.26
Price to Book1.07
Debt/Equity2.03
% Insiders57.887%
Growth
Revenue Growth-0.15%
Earnings Growth0.23%
Estimates
Forward P/E-16.12
Forward EPS-5.31
Target Mean Price112.40

DCF valuation

Model fair value for BioNTech SE (BNTX)
Result
Sign in to run the valuation for BNTX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
20 analysts · consensus Buy · mean target 112.40 USD (low 74.68, high 144.39) · as of 15 Nov 2026
Low 74.68
Mean 112.40
High 144.39
Price 85.60
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

BioNTech SE Logo BioNTech SE Analysis (BNTX)

Germany Health Care Official Website Stock

Is BioNTech SE a good investment? BioNTech SE (BNTX) is currently trading at 85.60 USD. Market analysts have a consensus price target of 112.40 USD. This suggests a potential upside from current levels.

Earnings Schedule: BioNTech SE is expected to release its next earnings report on March 9, 2027. The market consensus estimate for Forward EPS is -5.31.

Investor FAQ

Does BioNTech SE pay a dividend?

No, it does not currently pay a dividend.

What asset class is BioNTech SE?

BioNTech SE is classified as a Stock. You can compare it against 11 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be March 9, 2027. The company currently has a trailing EPS of -6.83.

Company Profile

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.

Exchange Ticker
VIE (Austria) BNTX.VI
HAM (Germany) 22UA.HM
MUN (Germany) 22UA.MU
GER (Germany) 22UA.DE
BER (Germany) 22UA.BE
DUS (Germany) 22UA.DU
NMS (United States) BNTX
FRA (Germany) 22UA.F
SAO (Brazil) B1NT34.SA
MEX (Mexico) BNTXN.MX
IOB (United Kingdom) 0A3M.IL
Trades
Dividend History paid per year (USD)
Historical Dividends
Year Total Dividends
▸2022
2.11 USD
June 17, 2022 2.1110
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion